Show simple item record

dc.contributor.authorReid, CE
dc.contributor.authorLi, H
dc.contributor.authorSur, G
dc.contributor.authorCarmillo, P
dc.contributor.authorBushnell, S
dc.contributor.authorTizard, R
dc.contributor.authorMcAuliffe, M
dc.contributor.authorTonkin, C
dc.contributor.authorSimon, K
dc.contributor.authorGoelz, S
dc.contributor.authorCinque, P
dc.contributor.authorGorelik, L
dc.contributor.authorCarulli, JP
dc.date.accessioned2020-12-17T03:13:19Z
dc.date.available2020-12-17T03:13:19Z
dc.date.issued2011-07-15
dc.identifierpii: jir256
dc.identifier.citationReid, C. E., Li, H., Sur, G., Carmillo, P., Bushnell, S., Tizard, R., McAuliffe, M., Tonkin, C., Simon, K., Goelz, S., Cinque, P., Gorelik, L. & Carulli, J. P. (2011). Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients. JOURNAL OF INFECTIOUS DISEASES, 204 (2), pp.237-244. https://doi.org/10.1093/infdis/jir256.
dc.identifier.issn0022-1899
dc.identifier.urihttp://hdl.handle.net/11343/254795
dc.description.abstractBACKGROUND: Progressive multifocal leukoencephalopathy (PML) in natalizumab-treated MS patients is linked to JC virus (JCV) infection. JCV sequence variation and rearrangements influence viral pathogenicity and tropism. To better understand PML development, we analyzed viral DNA sequences in blood, CSF and/or urine of natalizumab-treated PML patients. METHODS: Using biofluid samples from 17 natalizumab-treated PML patients, we sequenced multiple isolates of the JCV noncoding control region (NCCR), VP1 capsid coding region, and the entire 5 kb viral genome. RESULTS: Analysis of JCV from multiple biofluids revealed that individuals were infected with a single genotype. Across our patient cohort, multiple PML-associated NCCR rearrangements and VP1 mutations were present in CSF and blood, but absent from urine-derived virus. NCCR rearrangements occurred in CSF of 100% of our cohort. VP1 mutations were observed in blood or CSF in 81% of patients. Sequencing of complete JCV genomes demonstrated that NCCR rearrangements could occur without VP1 mutations, but VP1 mutations were not observed without NCCR rearrangement. CONCLUSIONS: These data confirm that JCV in natalizumab-PML patients is similar to that observed in other PML patient groups, multiple genotypes are associated with PML, individual patients appear to be infected with a single genotype, and PML-associated mutations arise in patients during PML development.
dc.languageEnglish
dc.publisherOXFORD UNIV PRESS INC
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleSequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
dc.typeJournal Article
dc.identifier.doi10.1093/infdis/jir256
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleJournal of Infectious Diseases
melbourne.source.volume204
melbourne.source.issue2
melbourne.source.pages237-244
dc.rights.licenseCC BY-NC
melbourne.elementsid1321727
melbourne.contributor.authorTonkin, Christopher
dc.identifier.eissn1537-6613
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record